Your browser is no longer supported. Please, upgrade your browser.
SELB Selecta Biosciences, Inc. daily Stock Chart
Selecta Biosciences, Inc.
Index- P/E- EPS (ttm)-0.83 Insider Own7.10% Shs Outstand105.33M Perf Week-6.14%
Market Cap348.89M Forward P/E- EPS next Y-0.23 Insider Trans117.12% Shs Float79.95M Perf Month-2.73%
Income-68.30M PEG- EPS next Q-0.12 Inst Own62.40% Short Float12.10% Perf Quarter47.25%
Sales11.30M P/S30.88 EPS this Y58.40% Inst Trans0.32% Short Ratio3.32 Perf Half Y-15.97%
Book/sh-0.07 P/B- EPS next Y63.50% ROA-61.50% Target Price- Perf Year115.44%
Cash/sh- P/C- EPS next 5Y- ROE- 52W Range1.42 - 4.83 Perf YTD34.87%
Dividend- P/FCF12.20 EPS past 5Y5.10% ROI-192.10% 52W High-33.54% Beta1.20
Dividend %- Quick Ratio2.20 Sales past 5Y17.00% Gross Margin- 52W Low126.06% ATR0.24
Employees27 Current Ratio2.20 Sales Q/Q- Oper. Margin- RSI (14)57.12 Volatility7.06% 6.88%
OptionableYes Debt/Eq- EPS Q/Q64.30% Profit Margin- Rel Volume0.49 Prev Close3.23
ShortableYes LT Debt/Eq- EarningsNov 05 BMO Payout- Avg Volume2.92M Price3.21
Recom2.30 SMA20-0.05% SMA5016.91% SMA20014.37% Volume1,416,469 Change-0.62%
Oct-01-20Downgrade William Blair Outperform → Mkt Perform
Oct-01-20Downgrade Mizuho Buy → Neutral $2.50
Jun-12-20Downgrade Stifel Buy → Hold
Apr-28-20Initiated H.C. Wainwright Buy $8
Jan-29-20Initiated Cantor Fitzgerald Overweight $10
Jan-21-20Initiated William Blair Outperform
Jun-27-18Initiated Janney Buy $33
Mar-30-17Reiterated UBS Buy $26
Nov-20-20 12:09PM  
Nov-19-20 08:00AM  
Nov-10-20 08:00AM  
Nov-09-20 08:42AM  
Nov-06-20 11:31PM  
Nov-05-20 10:14AM  
Oct-29-20 08:00AM  
Oct-27-20 12:35PM  
Oct-26-20 07:09AM  
Oct-21-20 11:58AM  
Oct-20-20 08:00AM  
Oct-13-20 12:25PM  
Oct-10-20 10:20AM  
Oct-09-20 07:20AM  
Oct-08-20 04:05PM  
Oct-01-20 04:38PM  
Sep-30-20 04:15PM  
Sep-24-20 04:17PM  
Sep-23-20 07:00AM  
Sep-08-20 08:00AM  
Sep-01-20 08:00AM  
Aug-28-20 03:38PM  
Aug-06-20 10:45AM  
Aug-04-20 12:47PM  
Aug-03-20 04:05PM  
Jul-30-20 08:00AM  
Jul-28-20 06:00AM  
Jul-23-20 11:30AM  
Jul-15-20 07:11AM  
Jun-23-20 04:05PM  
Jun-19-20 12:22PM  
Jun-18-20 08:30AM  
Jun-16-20 11:30AM  
Jun-15-20 08:00AM  
Jun-12-20 12:24PM  
Jun-11-20 05:15PM  
May-29-20 08:52AM  
May-26-20 08:00AM  
May-20-20 01:06PM  
May-18-20 10:04AM  
May-12-20 12:49PM  
May-08-20 02:30PM  
May-07-20 07:30AM  
May-06-20 12:04PM  
May-05-20 08:00AM  
Apr-30-20 08:00AM  
Apr-28-20 08:00AM  
Apr-07-20 08:00AM  
Mar-31-20 08:12AM  
Mar-12-20 08:00AM  
Mar-05-20 08:00AM  
Mar-03-20 03:00PM  
Feb-23-20 07:10AM  
Feb-18-20 08:00AM  
Dec-19-19 08:25AM  
Dec-16-19 07:53AM  
Nov-22-19 10:54AM  
Nov-21-19 08:00AM  
Nov-15-19 11:17PM  
Nov-12-19 08:00AM  
Nov-11-19 09:00AM  
Nov-08-19 08:00AM  
Nov-01-19 08:09AM  
Oct-24-19 08:00AM  
Oct-23-19 10:48AM  
Sep-04-19 08:00AM  
Sep-03-19 02:21PM  
Sep-02-19 04:55PM  
Aug-08-19 08:00AM  
Aug-07-19 07:35AM  
Aug-01-19 08:00AM  
Jul-31-19 08:00AM  
Jul-15-19 08:00AM  
Jun-28-19 08:38AM  
Jun-26-19 10:15AM  
Jun-21-19 08:39AM  
Jun-20-19 04:05PM  
Jun-15-19 10:36AM  
Jun-12-19 08:00AM  
May-30-19 08:00AM  
May-23-19 01:46AM  
May-09-19 08:00AM  
May-02-19 08:00AM  
Apr-16-19 04:05PM  
Apr-04-19 05:54AM  
Selecta Biosciences, Inc., a clinical-stage biopharmaceutical company, researches and develops nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. Its proprietary pipeline includes therapeutic enzymes, gene therapies, and other products and product candidates affected by undesired immune responses. The company's lead product is SEL-212 that has completed Phase II clinical trials for the treatment of chronic refractory gout. It also engages in the development of gene therapy product candidates that are in preclinical development for rare inborn errors of metabolism, including SEL-302, a therapy program for the treatment methylmalonic academia; and SEL-313, a product candidate to treat ornithine transcarbamylase deficiency. Selecta Biosciences, Inc. has license and collaboration agreements with Spark Therapeutics; Massachusetts Institute of Technology; Shenyang Sunshine Pharmaceutical Co., Ltd.; BIND Therapeutics, Inc.; Asklepios BioPharmaceutical, Inc. Sarepta Therapeutics, Inc.; and IGAN Biosciences, Inc. Selecta Biosciences, Inc. was founded in 2007 and is headquartered in Watertown, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Brunn CarstenPresident and CEODec 02Sale3.353,32311,134101,350Dec 03 04:22 PM
Brunn CarstenPresident and CEODec 01Option Exercise0.0010,9380104,673Dec 03 04:22 PM
Kishimoto Takashi KeiChief Scientific OfficerOct 23Option Exercise2.7730,00083,100126,149Oct 27 05:13 PM
SPRINGER TIMOTHY ADirectorOct 23Buy2.71994,4882,699,73714,480,948Oct 23 05:12 PM
SPRINGER TIMOTHY ADirectorOct 22Buy2.631,770,2044,656,69913,486,460Oct 23 05:12 PM
SPRINGER TIMOTHY ADirectorOct 21Buy2.50880,0002,199,47211,716,256Oct 23 05:12 PM
SPRINGER TIMOTHY ADirectorOct 20Buy2.21910,0002,013,19310,836,256Oct 20 06:07 PM
SPRINGER TIMOTHY ADirectorOct 19Buy2.36759,5001,795,0029,926,256Oct 20 06:07 PM
SPRINGER TIMOTHY ADirectorOct 16Buy2.42218,196528,0349,166,756Oct 20 06:07 PM
SPRINGER TIMOTHY ADirectorOct 09Buy2.00276,703552,4658,948,560Oct 14 04:18 PM
SPRINGER TIMOTHY ADirectorOct 08Buy1.89530,4411,000,8368,671,857Oct 08 05:50 PM
SPRINGER TIMOTHY ADirectorOct 07Buy1.65654,9531,078,5778,141,416Oct 08 05:50 PM
SPRINGER TIMOTHY ADirectorOct 06Buy1.682,000,0003,365,8007,486,463Oct 08 05:50 PM
BARABE TIMOTHY CDirectorOct 06Buy1.6850,00083,985171,013Oct 08 04:25 PM
Brunn CarstenPresident and CEOSep 02Sale2.393,3648,03593,735Sep 03 04:29 PM
Brunn CarstenPresident and CEOSep 01Option Exercise0.0010,937097,099Sep 03 04:29 PM
BARABE TIMOTHY CDirectorJun 24Option Exercise1.4632,84047,946121,013Jun 26 04:21 PM
Brunn CarstenPresident and CEOJun 02Sale3.863,25312,55786,162Jun 03 04:42 PM
Brunn CarstenPresident and CEOJun 01Option Exercise0.0010,938089,415Jun 03 04:42 PM
BARABE TIMOTHY CDirectorMar 17Buy2.005,00010,00088,173Mar 19 05:16 PM
Brunn CarstenPresident and CEOMar 03Sale3.863,37413,01178,477Mar 03 04:25 PM
Brunn CarstenPresident and CEOMar 01Option Exercise0.0010,937081,851Mar 03 04:25 PM
Johnston Lloyd P.COO and SVP, R&DJan 16Option Exercise0.475,1282,41016,734Jan 21 05:21 PM